


Baseline Characteristics Associated With Loss of BCVA ≥15 ETDRS Letters in Participants With Geographic Atrophy in the Phase 2 ARCHER Study

Usha Chakravarthy, FRCOphth, PhD, CBE¹ on behalf of the ARCHER and ARCHER II Investigators

¹Queen's University of Belfast, Institute of Clinical Science, Royal Victoria Hospital, Belfast, Northern Ireland, UK

ARCHER: Phase 2 Trial Of The C1q Inhibitor Vonaprument (ANX007) in Participants with GA



PRIMARY ENDPOINT

Rate of Change in GA lesion area as assessed
by fundus autofluorescence at Month 12

PRESPECIFIED FUNCTIONAL ANALYSES

Best Corrected Visual Acuity (BCVA)
Low Luminance Visual Acuity (LLVA) & Deficit (LLVD)

Off-treatment
(6 months)

END OF STUDY
Month 18


ARCHER Phase 2: Baseline Characteristics Generally Well-Balanced Across Arms

DEMOGRAPHICS AND CHARACTERISTICS AT BASELINE	Sham (N = 89)	Vonaprument EOM (N = 92)	Vonaprument EM (N = 89)
Age, mean (SD)	79.8 (7.5)	80.5 (8.5)	79.7 (8.6)
Gender – Female, n (%)	59 (66.3%)	60 (65.2%)	47 (52.8%)
Race – Caucasian, n (%)	86 (96.6%)	89 (96.7%)	88 (98.9%)
Mean BCVA, letters (SD)	58.5 (16.2)	57.9 (15.3)	58.8 (17.2)
Mean LLVA, letters (SD)	34.2 (18.1)	29.6 (15.7)	35.3 (16.4)
Mean GA Lesion Size, mm ² (SD)	7.28 (3.99)	7.53 (4.10)	7.28 (3.96)
Foveal Lesion (%)	49.4%	53.3%	57.3%
Multifocality, n (%)	65 (73.0%)	67 (72.8%)	61 (68.5%)

ARCHER Phase 2: Protection from Vision Loss Seen with Vonaprument

PATIENTS WITH CONFIRMED BCVA ≥15-LETTER LOSS THROUGH MONTH 12[#]

Month 12 event confirmed at month 15



Nominal p-value
vs sham[^]

.0994


.0076

*BCVA ≥15-Letter Loss at Month 12 was confirmed at the subsequent visit (Month 15). In ARCHER, visits were monthly through Month 12 and then at Months 15 & 18

[^]Nominal p-value from a Chi-square test in ITT population: *Nominal p < 0.05

PROBABILITY OF CONFIRMED BCVA ≥15-LETTER LOSS THROUGH MONTH 12[#]

Estimate of Kaplan-Meier Probability (%) of
Participants without ≥15 Letter BCVA Loss




HR, hazard ratio; Nominal log-rank test (versus sham) p-values are presented;

[#]Confirmed BCVA 15-LL at two consecutive visits including month 12 supported by ensuing (off-treatment) visit

ARCHER Phase 2: Vision Protection Seen Across Participant GA Types


PARTICIPANTS WITH CONFIRMED BCVA ≥15-LETTER LOSS THROUGH MONTH 12#



#15-LL Event Definition – confirmed loss of 15 or more letters by BCVA at two consecutive visits including month 12 supported month 15; Events: n = 27


ARCHER Phase 2: Baseline Visual Acuity Impacted 15-Letter Loss

BCVA ≥ 15 -LETTER LOSS EVENTS BY BASELINE BCVA



- BCVA ≥ 15 -letter loss:
 - Did not occur in participants with baseline BCVA <44 letters
 - Less frequent with baseline BCVA >69 letters


BCVA ≥ 15 -LETTER LOSS EVENTS BY BASELINE LLVA



- BCVA ≥ 15 -letter loss:
 - Did not occur in participants with baseline LLVA >50 letters
 - Less frequent with baseline LLVA >35 letters

ARCHER II Phase 3 Trial: Well-Informed Design and Powering

- Leverages Phase 2 learnings and enriched for patients with higher risk of vision loss



GLOBAL REGISTRATION PATH¹

Prime designation in EU
Selected by EMA for PDC² program
FDA Fast Track designation

PRIMARY ENDPOINT

Proportion of patients who experience
a BCVA ≥ 15 -Letter Loss confirmed at
two consecutive visits at
Month 15 or Month 24

SECONDARY ENDPOINTS

Safety, LLVA, EZ integrity

¹Single protocol analyzed as two sub-studies addresses FDA two-trial recommendation

²Product Development Coordinator

ARCHER II Study Design Optimized to Assess Vision Protection

- ARCHER II is the only global pivotal program with vision protection as the primary endpoint
- Learnings from the Phase 2 ARCHER study informed the ARCHER II design
 - Eyes with <45 BCVA letters at baseline excluded from ARCHER II
 - All participant GA types were included in ARCHER II, irrespective of lesion location, focality
- Vonaprumment (ANX007) has the potential to be the first pharmacologic treatment to protect vision in patients with dry AMD with GA
- Anticipated communications on track for Month 15 primary endpoint in Q4 2026 and Month 24 primary endpoint in Q3 2027